Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
The historical rank and industry rank for China Tian Yuan Healthcare Group's Return-on-Tangible-Equity or its related term are showing as below:
HKSE:00557'
s Return-on-Tangible-Equity Range Over the Past 10 Years
Min: -64.55 Med: -15.26 Max: 4.58
Current: -22.01
During the past 13 years, China Tian Yuan Healthcare Group's highest Return-on-Tangible-Equity was 4.58%. The lowest was -64.55%. And the median was -15.26%.
HKSE:00557's Return-on-Tangible-Equity is ranked worse than 92.26% of 530
companies
in the Credit Services industry
Industry Median: 7.26
vs HKSE:00557: -22.01
China Tian Yuan Healthcare Group (HKSE:00557) Return-on-Tangible-Equity Explanation
Return-on-Tangible-Equity measures the rate of return on the ownership interest (shareholder's tangible equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' tangible equity (shareholders equity minus intangibles). Return-on-Tangible-Equity shows how well a company uses investment funds to generate earnings growth. Return-on-Tangible-Equitys between 15% and 20% are considered desirable.
Be Aware
Net Income is used.
Because a company can increase its Return-on-Tangible-Equity by having more financial leverage, it is important to watch the leverage ratio when investing in high Return-on-Tangible-Equity companies. Like Return-on-Tangible-Asset, Return-on-Tangible-Equity is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their Return-on-Tangible-Equitys can be extremely high.
China Tian Yuan Healthcare Group Return-on-Tangible-Equity Related Terms
China Tian Yuan Healthcare Group Return-on-Tangible-Equity Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
China Tian Yuan Healthcare Group Return-on-Tangible-Equity Chart
HKSE:00557 vs V, MA, AXP: Return-on-Tangible-Equity Comparison
For the Credit Services subindustry, China Tian Yuan Healthcare Group's Return-on-Tangible-Equity, along with its competitors' market caps and Return-on-Tangible-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
China Tian Yuan Healthcare Group Return-on-Tangible-Equity vs Credit Services Industry
For the Credit Services industry and Financial Services sector, China Tian Yuan Healthcare Group's Return-on-Tangible-Equity distribution charts can be found below:
* The bar in red indicates where China Tian Yuan Healthcare Group's Return-on-Tangible-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Equity, the net income of the last fiscal year and the average total shareholder tangible equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is two times the semi-annual (Dec. 2025) net income data.
Return-on-Tangible-Equity is displayed in the 10-year financial page.
What does a Return-on-Tangible-Equity of -40.44% mean?
China Tian Yuan Healthcare Group (HKSE:00557) has a Return-on-Tangible-Equity of -40.44% as of Dec. 2025. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on China Tian Yuan Healthcare Group and its competitors. According to the industry distribution chart, China Tian Yuan Healthcare Group ranks #489 out of 530 companies in the Credit Services industry, placing it in the top 92.3%.
Is China Tian Yuan Healthcare Group's Return-on-Tangible-Equity too high?
China Tian Yuan Healthcare Group's current Return-on-Tangible-Equity is -40.44%. Based on the distribution chart, China Tian Yuan Healthcare Group ranks #489 out of 530 companies in the Credit Services industry, which is in the bottom quartile relative to peers. Overall, China Tian Yuan Healthcare Group has a GF Score™ of 28/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does China Tian Yuan Healthcare Group's Return-on-Tangible-Equity compare to V and MA?
According to the Credit Services industry distribution chart, China Tian Yuan Healthcare Group ranks #489 out of 530 companies for Return-on-Tangible-Equity. This places China Tian Yuan Healthcare Group in the lower half of its industry. The industry median Return-on-Tangible-Equity is 7.26. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Equity for a Credit Services company?
The median Return-on-Tangible-Equity among Credit Services companies is 7.26, based on 530 companies in the industry. Companies in the top quartile (top 25%) have a Return-on-Tangible-Equity significantly above this median, while those in the bottom quartile fall well below. However, Return-on-Tangible-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Equity mean?
A high Return-on-Tangible-Equity can signal that a stock is expensive relative to its fundamentals. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on China Tian Yuan Healthcare Group and its competitors. For the Credit Services industry, the median Return-on-Tangible-Equity is 7.26 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. China Tian Yuan Healthcare Group's current Return-on-Tangible-Equity is -40.44%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is China Tian Yuan Healthcare Group stock overvalued right now?
Based on GuruFocus' analysis, China Tian Yuan Healthcare Group (HKSE:00557) is currently considered Significantly Overvalued. The stock's GF Value™ is HK$0.32, compared to a current price of HK$0.55 — trading 70.3% above its estimated fair value. The current Return-on-Tangible-Equity is -40.44%. China Tian Yuan Healthcare Group's overall GF Score™ is 28/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Equity calculated?
Return-on-Tangible-Equity is calculated from a company's financial statements. For China Tian Yuan Healthcare Group (HKSE:00557), the current Return-on-Tangible-Equity is -40.44% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is China Tian Yuan Healthcare Group (HKSE:00557) Overvalued in 2026?
Based on GuruFocus' analysis, China Tian Yuan Healthcare Group stock appears to be overvalued.
The current stock price of HK$0.55 is trading 70.3% above its estimated GF Value™ of HK$0.32.
GuruFocus considers China Tian Yuan Healthcare Group to be Significantly Overvalued.
Key valuation signals for HKSE:00557:
Return-on-Tangible-Equity: -40.44%
GF Value™: HK$0.32 vs. price of HK$0.55 (70.3% above fair value)
No single metric tells the full story. See the HKSE:00557 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
China Tian Yuan Healthcare Group Ltd is an investment holding company engaged in investment holding, provision of procurement, marketing and management services to the medical industry, provision of procurement services relating to the hospitality industry, licensing of trademarks, and money lending and related business. Its segments include Investment Holding, Healthcare, Money Lending and Related Business, which generates maximum revenue from interests earned from the provision of loans to third parties, referral and handling fees for loan-related services, and the introduction of prospective lenders and borrowers in PRC and Hong Kong; and Hospitality. The company generates maximum revenue from Hong Kong.
28GF Score
Get the complete analysis for HKSE:00557
Return-on-Tangible-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HKSE:00557 has been successfully added to your 
